Genome-wide Association Study
This study is not yet open for participant recruitment.
Verified December 2011 by Samsung Medical Center
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
First received: December 21, 2011
Last updated: NA
Last verified: December 2011
History: No changes posted
To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.
Esophageal Squamous Cell Carcinoma.
||Observational Model: Cohort
Time Perspective: Prospective
||Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||June 2013 (Final data collection date for primary outcome measure)
Patients treated with Taxane/5-FU/platinum based chemo.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Esophageal squamous cell carcinoma Patients treated with Taxane/5-FU/platinum based chemotherapy.
- Histological confirmed esophageal squamous cell carcinoma
- Patients treated with Taxane or 5-FU or platinum based chemotherapy.
- provision of a signed written informed consent.
- patients not signed written informed consent.
- patient unacceptable for study in the judgement of the investigator.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01498757
Samsung Medical Center
No publications provided
||Jeeyun Lee, Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology, Samsung Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 21, 2011
||December 21, 2011
||Korea: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 18, 2013
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Digestive System Diseases